-
Your prediction
Pros and Cons of Advanced Proteome Therapeutics in the next few years
Pros
Cons
Performance of Advanced Proteome Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Advanced Proteome Therapeutics | - | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | 0.740% | -7.432% | -23.464% | 31.731% | -17.470% | -21.714% | -58.168% |
| Northwest Biotherapeutics Inc. | 0.000% | -6.077% | -5.556% | -32.000% | -17.476% | -69.091% | -87.023% |
| Celldex Therapeutics | 3.180% | -5.987% | -6.853% | 46.127% | 14.909% | -14.595% | 10.201% |
News
These Were the Best-Performing Asset Classes in May. Can They Continue to Lead?
May was a good month for most asset classes. U.S. stocks and international stocks (both developed and emerging market) advanced strongly during the month. Several bond categories were also up for
AI Employees Are Coming. 3 Stocks Wall Street Thinks Will Benefit Most
It's been more than three years since the launch of ChatGPT, which started the current artificial intelligence (AI) revolution. It's now clear that this isn't just a fad. AI is changing many aspects
Nvidia Wants to Reinvent the PC. Here's What That Means for Intel, AMD, and Qualcomm.
Nvidia (NASDAQ: NVDA) has spent the past three years becoming the world's most valuable company on the back of one business: selling the chips that power artificial intelligence (AI) data centers


